Silence Therapeutics (LON:SLN)‘s stock had its “buy” rating restated by Peel Hunt in a research report issued to clients and investors on Monday. They currently have a GBX 277 ($3.83) target price on the stock. Peel Hunt’s target price indicates a potential upside of 53.89% from the company’s current price.
Shares of Silence Therapeutics (SLN) opened at GBX 180 ($2.49) on Monday. Silence Therapeutics has a 12-month low of GBX 71.88 ($0.99) and a 12-month high of GBX 254.75 ($3.52). The stock has a market capitalization of $136.14 and a price-to-earnings ratio of -9,000.00.
Silence Therapeutics (LON:SLN) last issued its quarterly earnings data on Tuesday, March 6th. The company reported GBX (2.30) (($0.03)) earnings per share (EPS) for the quarter. Silence Therapeutics had a negative return on equity of 21.42% and a negative net margin of 34,475.00%. The business had revenue of GBX 2 million during the quarter.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3301720/silence-therapeutics-sln-receives-buy-rating-from-peel-hunt.html.
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.